MHRA — authorised 12 April 2006
- Marketing authorisation holder: SANDOZ GMBH
- Status: approved
🇬🇧 Omnitrope in United Kingdom
MHRA authorised Omnitrope on 12 April 2006 · NICE has issued 2 UK HTA decisions
Marketing authorisation
Health technology assessment
2 decisions from NICE for Omnitrope in United Kingdom.
NICE TA188 — — Decision pending classification
- Indication assessed: the treatment of growth failure in children
NICE made a decision on Omnitrope for the treatment of growth failure in children. The decision was based on the drug's cost and effectiveness. However, the specific details of the decision, including the cost basis and any restrictions, are not provided.
NICE TA64 — ✓ Recommended
NICE recommended Omnitrope for a specific indication. However, the exact indication is not specified in the provided information. The decision was made without a reported cost-effectiveness analysis or a Patient Access Scheme.
Omnitrope in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Omnitrope approved in United Kingdom?
Yes. MHRA authorised it on 12 April 2006.
Who is the marketing authorisation holder for Omnitrope in United Kingdom?
SANDOZ GMBH holds the UK marketing authorisation.
Has Omnitrope been assessed by UK health technology agencies?
Yes — 2 UK HTA decisions on record from NICE.